inclusion criteria: * aged 18 years or older on the day of inclusion. * for persons living with human immunodeficiency virus (hiv), stable hiv infection determined by participant currently on antiretrovirals with cd4 count \> 200/mm3. * sars-cov-2 rapid serodiagnostic test performed at the time of enrollment to detect presence of sars-cov-2 antibodies. * does not intend to receive an authorized/approved covid-19 vaccine despite encouragement by the investigator to receive the authorized vaccine available to them at the time of enrollment. * informed consent form has been signed and dated * able to attend all visits and to comply with all study procedures * covered by health insurance, only if required by local, regional or national regulations * a female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies: * is of non-childbearing potential. to be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year or surgically sterile, or * is of childbearing potential and agrees to use an effective contraceptive method or abstinence from at least 4 weeks prior to the first study intervention administration until at least 12 weeks after the second study intervention administration. a participant of childbearing potential must have a negative highly sensitive pregnancy test (urine or serum as required by local regulation) within 25 hours before any dose of study intervention.

inclusion criteria: * aged 18 years or older on the day of inclusion. * for persons living with human immunodeficiency virus (hiv), stable hiv infection determined by participant currently on antiretrovirals with cd4 count \> 200/mm3. * sars-cov-2 rapid serodiagnostic test performed at the time of enrollment to detect presence of sars-cov-2 antibodies. * does not intend to receive an authorized/approved covid-19 vaccine despite encouragement by the investigator to receive the authorized vaccine available to them at the time of enrollment. * informed consent form has been signed and dated * able to attend all visits and to comply with all study procedures * covered by health insurance, only if required by local, regional or national regulations * a female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies: * is of non-childbearing potential. to be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year or surgically sterile, or * is of childbearing potential and agrees to use an effective contraceptive method or abstinence from at least 4 weeks prior to the first study intervention administration until at least 12 weeks after the second study intervention administration. a participant of childbearing potential must have a negative highly sensitive pregnancy test (urine or serum as required by local regulation) within 25 hours before any dose of study intervention.

inclusion criteria: aged 18 years or older on the day of inclusion. for persons living with human immunodeficiency virus (hiv), stable hiv infection determined by participant currently on antiretrovirals with cd4 count > 200/mm3. sars-cov-2 rapid serodiagnostic test performed at the time of enrollment to detect presence of sars-cov-2 antibodies. does not intend to receive an authorized/approved covid-19 vaccine despite encouragement by the investigator to receive the authorized vaccine available to them at the time of enrollment. informed consent form has been signed and dated able to attend all visits and to comply with all study procedures covered by health insurance, only if required by local, regional or national regulations a female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies: is of non-childbearing potential. to be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year or surgically sterile, or is of childbearing potential and agrees to use an effective contraceptive method or abstinence from at least 4 weeks prior to the first study intervention administration until at least 12 weeks after the second study intervention administration. a participant of childbearing potential must have a negative highly sensitive pregnancy test (urine or serum as required by local regulation) within 25 hours before any dose of study intervention.

inclusion criteria: aged 18 years or older on the day of inclusion. for persons living with human immunodeficiency virus (hiv), stable hiv infection determined by participant currently on antiretrovirals with cd4 count > 200/mm3. sars-cov-2 rapid serodiagnostic test performed at the time of enrollment to detect presence of sars-cov-2 antibodies. does not intend to receive an authorized/approved covid-19 vaccine despite encouragement by the investigator to receive the authorized vaccine available to them at the time of enrollment. informed consent form has been signed and dated able to attend all visits and to comply with all study procedures covered by health insurance, only if required by local, regional or national regulations a female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies: is of non-childbearing potential. to be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year or surgically sterile, or is of childbearing potential and agrees to use an effective contraceptive method or abstinence from at least 4 weeks prior to the first study intervention administration until at least 12 weeks after the second study intervention administration. a participant of childbearing potential must have a negative highly sensitive pregnancy test (urine or serum as required by local regulation) within 25 hours before any dose of study intervention.

inclusion criteria: - aged 18 years or older on the day of inclusion. - for persons living with human immunodeficiency virus (hiv), stable hiv infection determined by participant currently on antiretrovirals with cd4 count > 200/mm3. - sars-cov-2 rapid serodiagnostic test performed at the time of enrollment to detect presence of sars-cov-2 antibodies. - does not intend to receive an authorized/approved covid-19 vaccine despite encouragement by the investigator to receive the authorized vaccine available to them at the time of enrollment. - a female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies: - is of non-childbearing potential. to be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year or surgically sterile, or - is of childbearing potential and agrees to use an effective contraceptive method or abstinence from at least 4 weeks prior to the first study intervention administration until at least 12 weeks after the second study intervention administration. a participant of childbearing potential must have a negative highly sensitive pregnancy test (urine or serum as required by local regulation).

inclusion criteria: - aged 18 years or older on the day of inclusion. - for persons living with human immunodeficiency virus (hiv), stable hiv infection determined by participant currently on antiretrovirals with cd4 count > 200/mm3. - sars-cov-2 rapid serodiagnostic test performed at the time of enrollment to detect presence of sars-cov-2 antibodies. - does not intend to receive an authorized/approved covid-19 vaccine despite encouragement by the investigator to receive the authorized vaccine available to them at the time of enrollment. - a female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies: - is of non-childbearing potential. to be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year or surgically sterile, or - is of childbearing potential and agrees to use an effective contraceptive method or abstinence from at least 4 weeks prior to the first study intervention administration until at least 12 weeks after the second study intervention administration. a participant of childbearing potential must have a negative highly sensitive pregnancy test (urine or serum as required by local regulation).